NASDAQ:NAUT Nautilus Biotechnology (NAUT) Stock Forecast, Price & News $3.46 -0.05 (-1.42%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$3.42▼$3.6050-Day Range$2.87▼$3.9452-Week Range$1.50▼$4.65Volume65,928 shsAverage Volume106,421 shsMarket Capitalization$432.26 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Nautilus Biotechnology MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside73.4% Upside$6.00 Price TargetShort InterestBearish1.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.64) to ($0.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.71 out of 5 starsMedical Sector841st out of 961 stocksAnalytical Instruments Industry24th out of 27 stocks 3.0 Analyst's Opinion Consensus RatingNautilus Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Nautilus Biotechnology has a forecasted upside of 73.4% from its current price of $3.46.Amount of Analyst CoverageNautilus Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted1.89% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Nautilus Biotechnology has recently increased by 8.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNautilus Biotechnology does not currently pay a dividend.Dividend GrowthNautilus Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NAUT. Previous Next 3.7 News and Social Media Coverage News SentimentNautilus Biotechnology has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nautilus Biotechnology this week, compared to 0 articles on an average week.Search Interest4 people have searched for NAUT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows4 people have added Nautilus Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nautilus Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders42.50% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 35.90% of the stock of Nautilus Biotechnology is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.64) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nautilus Biotechnology is -7.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nautilus Biotechnology is -7.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNautilus Biotechnology has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nautilus Biotechnology (NASDAQ:NAUT) StockNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington.Read More NAUT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NAUT Stock News HeadlinesSeptember 16, 2023 | americanbankingnews.comNautilus Biotechnology (NASDAQ:NAUT) Shares Up 12.3%September 8, 2023 | wsj.comNautilus Biotechnology Inc.September 21, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 6, 2023 | finance.yahoo.comNautilus Biotechnology to Participate in Upcoming September Investor ConferencesAugust 17, 2023 | finance.yahoo.comWith 33% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's futureAugust 3, 2023 | msn.comSilicon Valley's biotech sector is still going strong amid concerns about economyAugust 3, 2023 | axios.comSilicon Valley's biotech sector is still going strongAugust 2, 2023 | finanznachrichten.deNautilus Biotechnology Inc.: Nautilus Biotechnology Reports Second Quarter 2023 Financial ResultsSeptember 21, 2023 | Investor Place Media (Ad)Disturbing Truth About Biden's New Program To Seize Your CashA former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.August 2, 2023 | msn.comMarcus GAAP EPS of $0.35 beats by $0.06, revenue of $207M beats by $8.27MAugust 2, 2023 | msn.comNautilus Biotechnology GAAP EPS of -$0.13 beats by $0.01July 26, 2023 | benzinga.comSpectrometry Market is Rising at 7.1% CAGR to Surpass US$ 37.55 Billion by 2033: Fact.MR ReportJuly 11, 2023 | finance.yahoo.comNautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023June 28, 2023 | finance.yahoo.comDespite Nautilus Biotechnology's Pullback, Insiders Still Gained US$167kMay 18, 2023 | finance.yahoo.comNautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth PlansMay 3, 2023 | finance.yahoo.comQ1 2023 Nautilus Biotechnology Inc Earnings CallApril 23, 2023 | seekingalpha.comNautilus Biotechnology: The Rubber Will Soon Meet The RoadApril 18, 2023 | finance.yahoo.comNautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023March 7, 2023 | finance.yahoo.comNautilus Biotechnology Announces “First Access Challenge” WinnersMarch 1, 2023 | insidermonkey.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2022 Earnings Call TranscriptFebruary 23, 2023 | finanznachrichten.deNautilus Biotechnology Inc.: Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial ResultsFebruary 23, 2023 | msn.comNautilus Biotechnology GAAP EPS of -$0.11 beats by $0.03January 26, 2023 | finance.yahoo.comNautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023January 24, 2023 | seekingalpha.comNAUT Nautilus Biotechnology, Inc.November 1, 2022 | msn.comRecap: Nautilus Biotechnology Q3 EarningsNovember 1, 2022 | finance.yahoo.comNautilus Biotechnology Reports Third Quarter 2022 Financial ResultsOctober 5, 2022 | finance.yahoo.comNautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022See More Headlines Receive NAUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address NAUT Company Calendar Last Earnings8/02/2023Today9/21/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NAUT CUSIPN/A CIK1808805 Webwww.nautilus.bio Phone206-333-2001FaxN/AEmployees153Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+73.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-18.89% Return on Assets-16.81% Debt Debt-to-Equity RatioN/A Current Ratio21.13 Quick Ratio21.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.53 per share Price / Book1.37Miscellaneous Outstanding Shares124,930,000Free Float71,835,000Market Cap$432.26 million OptionableOptionable Beta1.18 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Sujal M. Patel (Age 48)Co-Founder, CEO, Pres, Sec. & Director Comp: $501.2kDr. Parag Mallick Ph.D. (Age 45)Co-Founder, Chief Scientist & Director Comp: $400kMs. Anna Mowry (Age 40)CFO & Treasurer Comp: $467.57kMs. Gwen E. Weld (Age 65)Chief People Officer Comp: $390.97kMs. Mary E. Godwin (Age 64)Sr. VP of Operations Mr. Matthew B. Murphy ESQ. (Age 58)Gen. Counsel Mr. Chris BlessingtonVP of Corp. Marketing & CommunicationsMr. Nick A. Nelson (Age 40)Chief Bus. Officer & Sr. VP of Bus. Devel. Dr. Subra Sankar Ph.D. (Age 64)Sr. VP of Product Devel. More ExecutivesKey CompetitorsEyePoint PharmaceuticalsNASDAQ:EYPTStandard BioToolsNASDAQ:LABAkoya BiosciencesNASDAQ:AKYASeerNASDAQ:SEERBionano GenomicsNASDAQ:BNGOView All CompetitorsInsiders & InstitutionsWolverine Trading LLCSold 33,700 shares on 8/23/2023Ownership: 0.000%Nuveen Asset Management LLCBought 24,809 shares on 8/16/2023Ownership: 0.154%Goldman Sachs Group Inc.Bought 3,396 shares on 8/15/2023Ownership: 0.076%Wells Fargo & Company MNBought 10,739 shares on 8/15/2023Ownership: 0.016%Alliancebernstein L.P.Bought 15,840 shares on 8/15/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions NAUT Stock - Frequently Asked Questions Should I buy or sell Nautilus Biotechnology stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares. View NAUT analyst ratings or view top-rated stocks. What is Nautilus Biotechnology's stock price forecast for 2023? 1 equities research analysts have issued 1 year target prices for Nautilus Biotechnology's stock. Their NAUT share price forecasts range from $6.00 to $6.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 73.4% from the stock's current price. View analysts price targets for NAUT or view top-rated stocks among Wall Street analysts. How have NAUT shares performed in 2023? Nautilus Biotechnology's stock was trading at $1.80 at the beginning of the year. Since then, NAUT stock has increased by 92.2% and is now trading at $3.46. View the best growth stocks for 2023 here. When is Nautilus Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our NAUT earnings forecast. How were Nautilus Biotechnology's earnings last quarter? Nautilus Biotechnology, Inc. (NASDAQ:NAUT) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.04. What is Nautilus Biotechnology's stock symbol? Nautilus Biotechnology trades on the NASDAQ under the ticker symbol "NAUT." Who are Nautilus Biotechnology's major shareholders? Nautilus Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.89%), Geode Capital Management LLC (0.81%), State Street Corp (0.75%), Northern Trust Corp (0.43%), Sentinel Trust Co. LBA (0.22%) and Nuveen Asset Management LLC (0.15%). Insiders that own company stock include Anna Mowry, Gwen E Weld, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, Subramanian Sankar and Sujal M Patel. View institutional ownership trends. How do I buy shares of Nautilus Biotechnology? Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nautilus Biotechnology's stock price today? One share of NAUT stock can currently be purchased for approximately $3.46. How much money does Nautilus Biotechnology make? Nautilus Biotechnology (NASDAQ:NAUT) has a market capitalization of $432.26 million. The company earns $-57,920,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. How many employees does Nautilus Biotechnology have? The company employs 153 workers across the globe. How can I contact Nautilus Biotechnology? Nautilus Biotechnology's mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.nautilus.bio. The company can be reached via phone at 206-333-2001 or via email at investorrelations@nautilus.bio. This page (NASDAQ:NAUT) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.